RecruitingNot Applicable

Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab

South Korea100 participantsStarted 2024-09-23

Plain-language summary

The goal of this observational study is to evaluate the clinical efficacy and safety of lenvatinib plus pembrolizumab combination therapy in patients with advanced biliary tract cancer (BTC). This study aims to identify potential biomarkers that may predict treatment response by analyzing genetic data from blood and tissue samples. The study will focus on real-world clinical outcomes and the exploratory discovery of biomarkers associated with the efficacy of this treatment regimen.

Who can participate

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with histologically or cytologically confirmed advanced biliary tract cancer. * Patients scheduled to receive Lenvatinib + Pembrolizumab for the treatment of advanced biliary tract cancer. * ECOG performance status of 0-2. * Patients aged 20 years or older at the time of treatment initiation. * Patients who understand and consent to participate in this study, and agree to provide samples obtained during the examination process. Exclusion Criteria: * Patients who do not consent to participate in the study or withdraw their consent.

What they're measuring

collected tumor samples

Timeframe: through study competition, an average of 2 years

Collected Blood Samples

Timeframe: Through study completion, an average of 2 years

Trial details

NCT IDNCT06648057

SponsorCHA University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-09-23

Contact for this trial

Hong Jae Chon, MD. PhD

82-31-780-3928 minidoctor@cha.ac.kr

View on ClinicalTrials.gov More Biliary Tract Cancer trials